Diagnostics News and Research

RSS

GHTC report confronts key challenge of renewing US leadership in global health technology

Today, the world is looking to the United States for cutting-edge diagnostics, drugs, and vaccines that could have the last word on an Ebola outbreak that is down but not out. But those innovations are the product of past US investments in research and development (R&D).

13 Mar 2015

Kalorama Information: Budding market for digital PCR reached 175 million in 2014

Kalorama Information estimated the budding market for digital PCR reached 175 million in 2014. The market research publisher said companies will be looking to provide products to increase research and diagnostics in diseases like cancer and neurological disorders.

13 Mar 2015

Melbourne researchers develop new genome editing technology to kill blood cancer cells

Melbourne researchers have developed a new genome editing technology that can target and kill blood cancer cells with high accuracy.

12 Mar 2015

Study supports use of ThyraMIR, ThyGenX Thyroid Oncogene Panel to improve thyroid cancer diagnosis

PDI, Inc. subsidiary, Interpace Diagnostics, announced today new data supporting the use of combination platform testing with ThyraMIR, the first and only microRNA expression classifier, and ThyGenX Thyroid Oncogene Panel, a DNA and RNA mutational analysis, to improve thyroid cancer diagnosis.

11 Mar 2015

Quest Diagnostics to provide whole exome sequencing service to diagnose neurological disorders

Quest Diagnostics, the world's leading provider of diagnostic information services, today announced the availability of Neurome, a whole exome sequencing service designed to aid the diagnosis of rare neurological disorders in pediatric populations.

From Quest Diagnostics 10 Mar 2015

NMR screening solution specifically for the analysis of honey launched by Bruker

This new NMR screening solution specifically for the analysis of honey is the most recent module of Bruker’s well-established FoodScreener™ product line to be released in April.

From Bruker 10 Mar 2015

Wine-Profiling solution based on NMR introduced by Bruker

This substantially enhanced second-generation module of the FoodScreener™ for wine profiling allows easy and cost-efficient NMR-based wine analysis, now for the first time also for key regions in France, Italy and Spain. In addition to geographical origin, NMR Wine Profiling can determine further key authenticity parameters such as grape variety, vintage year and possible water addition. This comprehensive solution offers a quick, fully automated and cost-efficient tool to ensure wine quality and authenticity, protecting brand integrity and consumer confidence.

From Bruker 10 Mar 2015

PTS Diagnostics announces launch of PTS Connect Wellness Solution

PTS Diagnostics, the U.S.-based manufacturer of both the CardioChek brand and the A1CNow family of point-of-care diagnostic products, announces the launch of the PTS Connect Wellness Solution. This secure cloud-based solution will empower health screening companies to screen more individuals faster and corporate wellness programs to improve outcomes by encouraging participants to monitor and track activity and progress online.

10 Mar 2015

Nuclear medicine in Australia: an interview with Doug Cubbin, ANM Board Chairman

Molybdennum-99 is a central part of Australia’s modern medical system, and is by far the most commonly used radioisotope produced by ANSTO. It decays to Technetium-99m, which is potentially lifesaving as it is used in the diagnosis of heart, conditions, as well as diagnostic procedures associated with kidneys, lungs, bone and the liver.

10 Mar 2015

Advanced Cell Diagnostics' RNAscope technology supports biomarker-selected phase 2 clinical trial of Merrimack Pharmaceuticals' MM-121

Advanced Cell Diagnostics, Inc. (ACD) announced today that Merrimack Pharmaceuticals, Inc. is using ACD's RNAscope technology to select patients for its Phase 2 clinical trial of its product candidate MM-121.

From Advanced Cell Diagnostics 9 Mar 2015

IDT’s CRISPR/Cas9 online resource for all your genome editing needs

Integrated DNA Technologies (IDT) has pooled its expertise in genome editing into a free web resource dedicated to providing researchers a hub of information on the very latest in using the CRISPR/Cas9 system.

From Integrated DNA Technologies 9 Mar 2015

Blood gas testing: an interview with David Stein, PhD, CEO, Point of Care, Siemens Healthcare Diagnostics

The industry term ‘blood gas testing’ has come to mean the accurate measurement and reporting of a wide menu of blood parameters, all on a single platform.

From Siemens Healthineers Point of Care Diagnostics 9 Mar 2015

Myriad Publishes myPath™ Melanoma Pivotal Validation Study in the Journal of Cutaneous Pathology

Myriad Genetics, Inc. (NASDAQ: MYGN) today announced the Journal of Cutaneous Pathology published data from a pivotal clinical validation study that showed the myPath™ Melanoma test is highly effective at differentiating benign skin moles from malignant melanoma with greater than 90 percent diagnostic accuracy. Melanoma is the most dangerous type of skin cancer and more than 76,000 new cases of melanoma are diagnosed each year in the United States.

6 Mar 2015

CRISPR-Cas9 gene-editing technology targets every gene in the genome in animal cancer model

For the first time, CRISPR-Cas9 gene-editing technology has been employed in a whole organism model to systematically target every gene in the genome.

6 Mar 2015

European launch of the Proxima miniature in-line blood gas analyser at ISICEM 2015

Sphere Medical, innovator in critical care monitoring and diagnostics equipment, will launch its ground-breaking in-line patient dedicated arterial blood gas analyser in Germany, Netherlands and Belgium at ISICEM 2015.

5 Mar 2015

VolitionRx begins pilot study to assess feasibility of NuQ assays in detecting prostate cancer

VolitionRx Limited, a life sciences company focused on developing blood-based diagnostic tests for a broad range of cancer types and other conditions, today announced that it has initiated a pilot study to assess the feasibility of VolitionRx's proprietary NuQ assays in detecting prostate cancer.

5 Mar 2015

Phase III trial to test VSV-EBOV vaccine for preventing Ebola to be launched in Guinea

Based on promising data from initial clinical trials in late 2014, WHO with the Health Ministry of Guinea, Médecins Sans Frontières, Epicentre and The Norwegian Institute of Public Health, will launch a Phase III trial in Guinea on 7 March to test the VSV-EBOV vaccine for efficacy and effectiveness to prevent Ebola.

5 Mar 2015

Hitachi Aloka Medical announces release of Ultrasound Bone Densitometry System at ECR 2015

Mr Minoru Yoshizumi, President of Hitachi Aloka Medical Ltd., Tokyo, Japan, is pleased to announce the release of EggQus, an extraordinary compact, portable Ultrasound Bone Densitometry System at the European Radiology Congress. Delegates will have the opportunity to see and test EggQus at the Hitachi Medical Systems booth 323, Expo C.

5 Mar 2015

Philips, UC Irvine partner to explore effectiveness of spectral imaging in breast density measurement

Royal Philips today announced its collaboration with the University of California, Irvine, to explore how spectral breast imaging can improve breast density measurement, potentially aiding clinicians in more accurately gauging breast cancer risks and monitoring changes over time.

5 Mar 2015

GeneSight test better predicts antidepressant outcomes for patients with depression

The combinatorial, multi-gene GeneSight test has been found to better predict antidepressant treatment outcomes for patients with depression, and their use of health care resources, than any of the individual genes that comprise the test, according to a peer-reviewed analysis by investigators from the Mayo Clinic and Assurex Health, and published online by The Pharmacogenomics Journal.

5 Mar 2015

Diagnostics News and Research

GHTC report confronts key challenge of renewing US leadership in global health technology

Kalorama Information: Budding market for digital PCR reached 175 million in 2014

Melbourne researchers develop new genome editing technology to kill blood cancer cells

Study supports use of ThyraMIR, ThyGenX Thyroid Oncogene Panel to improve thyroid cancer diagnosis

Quest Diagnostics to provide whole exome sequencing service to diagnose neurological disorders

NMR screening solution specifically for the analysis of honey launched by Bruker

Wine-Profiling solution based on NMR introduced by Bruker

PTS Diagnostics announces launch of PTS Connect Wellness Solution

Nuclear medicine in Australia: an interview with Doug Cubbin, ANM Board Chairman

Advanced Cell Diagnostics' RNAscope technology supports biomarker-selected phase 2 clinical trial of Merrimack Pharmaceuticals' MM-121

IDT’s CRISPR/Cas9 online resource for all your genome editing needs

Blood gas testing: an interview with David Stein, PhD, CEO, Point of Care, Siemens Healthcare Diagnostics

Myriad Publishes myPath™ Melanoma Pivotal Validation Study in the Journal of Cutaneous Pathology

CRISPR-Cas9 gene-editing technology targets every gene in the genome in animal cancer model

European launch of the Proxima miniature in-line blood gas analyser at ISICEM 2015

VolitionRx begins pilot study to assess feasibility of NuQ assays in detecting prostate cancer

Phase III trial to test VSV-EBOV vaccine for preventing Ebola to be launched in Guinea

Hitachi Aloka Medical announces release of Ultrasound Bone Densitometry System at ECR 2015

Philips, UC Irvine partner to explore effectiveness of spectral imaging in breast density measurement

GeneSight test better predicts antidepressant outcomes for patients with depression

Event guide: 16th Clinical Biomarkers & CDx Summit Europe eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News